Staining of antinuclear antibodies and antibodies against removable nuclear antigens in connective tissue diseases
Main Article Content
Keywords
Antibodies against extractable nuclear antigens, Anti-Nuclear antibody staining pattern, Connective tissue diseases, Immunoblot, Indirect immunofluorescence
Abstract
Introduction and objectives: Connective tissue diseases are inflammatory, autoimmune diseases and threaten quality of life. To determine the relationship between staining patterns of antinuclear antibodies and antibodies against extractable nuclear antigens in patients with connective tissue disease.
Materials and methods: Observational, basic, analytical and transversal study. Study conducted in the Immunology Service of the Arzobispo Loayza National Hospital between January 2017 and June 2017. We analyzed 291 samples of patients with CTD and for the detection of antinuclear antibody staining patterns, the immunological kit and observation with microscope of at 40X Immunofluorescence and for the detection of the antibodies against extractable nuclear antigens. The Immunoblot method was employed. Statistical analyses were carried out with the statistical package SPSS version 21 for Windows. We used the Pearson Chi-square test for the categorical variables, a value of p < 0.05 was considered significant.
Results: There was a significant relationship p < 0.05 of the homogeneous pattern, the mottled pattern with Anti-histones (p = 0.000), Anti-nucleosomes (p = 0.000), Anti-Ro 52 (p = 0.000), AntiSSA (p = 0.001), Anti-SSB (p = 0.003), Anti-dsDNA (p = 0.000) with the Pearson Chi-square test. There was a significant relationship of p < 0.05 of the centromeric pattern with Anti-Cenp B (p = 0.000) with Fishers exact statistic.
Conclusions: There was a significant relationship between the anti-nuclear antibody staining patterns and the antibodies to the core extractable antigens in patients with systemic lupus erythematosus, Sjögrens syndrome, Calcinosis, Raynauds phenomenon, esophageal Dysmotility, sclerodactyly and Telangiectasia (CREST), Scleroderma and Polymyositis.
References
2. Abumohor P. Connective tissue diseases: importance of early diagnosis. Med J Las Condes Clinic. 2012;23(4):391-400.
3. Hargraves M, Richmond H, Morton R. Presentation of two bone marrow components; the tart cell and the L.E. cell. Proc Staff Meet Mayo Clin. 1948;23(2):25-8.
4. Pisetsky D. The immunopathogenesis and immunopathology of systemic lupus erythematosus. In: En P, Schur H, Massarotti EM, editors. Lupus erythematosus: clinical evaluation and treatment. New York, US: Springer Science; 2012. p. 13-4.
5. Coons A, Kaplan M. Localization of antigen in tissue cells II: improvements in a method for the detection of antigen by means of fluorescent antibody. Int J Clin Exp Med. 1950;91(1):1-13.
6. Hoffman I, Peene I, Veys E. Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody Immunofluorescence Screening Tests. Am Assoc Clin Chem. 2002;48(12):2171-6.
7. Stinton L, Fritzler M. A clinical approach to autoantibody testing in systemic autoimmune rheumatic disorders. Autoimmun Rev. 2007;7(1):77-84.
8. Sontheimer R, McCauliffe D, Zappi E, Targoff I. Antinuclear antibodies: clinical correlations and biologic significance. Adv Dermatol. 1992;7(1):3-52.
9. Cruzado M. Study of ANA in patients with diagnostic suspicion of connective tissue diseases, treated at the National Hospital Dos de Mayo February 2005 to February 2006. In: Thesis specialty in clinical pathology. Lima, Peru: National University of San Marcos; 2006, 59pp.
10. Kavanaugh A, Tomar R, Reveille J. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigen. American College of Pathologists. Arch Pathol Lab Med. 2000;124(1):71-81.
11. Bielsa Y. Biological significance of the antibodies and techniques for their detection. Ibero Latin American Cutaneous Med. 2010;38(3):109-16.
12. Benitez C, Caballero O, Quintero J. Concordance between the determination of antinuclear antibodies by immunofluorescence and linear immunoassay. J Med Lab. 2011;17(9):429-43.
13. Bovone N, Fuentes M, Eposto M. Detection of anti-nucleus antibodies with linear immunoassay. Correlation with Indirect Immunofluorescence. Lat Am J Aquat Res. 2005;39(4):423-8.
14. Sharmin S, Ahmed S, Abu A, Rahman F, Choudhury M, Hassan M. Association of the immunofluorescence pattern of the antinuclear antibody with specific autoantibodies in the population of Bangladesh. Bangladesh Med Res Counc Bull. 2014;40(2):74-8.
15. WHO OMS. Environmental Health Criteria 236. Principles and methods for assessing autoimmunity associated with exposure to chemicals. First draft prepared by the World Health Organization. In: En MSheffer, editor. WHO Library Cataloguing-in-Publication. Ottawa, Canada: Wissenchaftliche Verlagsgesellschaft mbH; 2006, p.359.
16. Carballo O, Ingénito F, Ginaca A. First Argentine Consensus for the Standardization of the Determination of Anti-Nuclear Antibodies by Indirect Immunofluorescence-Hep-2. J Immunol. 2012;46(1):3-13.
17. CLSI. Quality Assurance of Laboratory Tests for Autoantibodies to Nuclear Antigens: (1) Indirect Fluorescence Assay for Microscopy and (2) Microtiter Enzyme Immunoassay Methods; Approved Guideline-. second edition Wayne PA: Clinical and Laboratory Standars Institute; 2006. CLSI document I/LA2-A2E. p.40.
18. ICAP, Retrieved from: International Consensus on ANA Patterns; 2015 https://www.anapatterns.org
19. Fernandez T, Sánchez C, Junco R. Diagnostic importance of antinuclear antibodies. Cuban J Rheum. 2016;18(2):192-5.
20. Molina J. The laboratory in rheumatic autoimmune diseases. J Med Lab. 2007;13(1-2):11-33.
21. Benitez C, Caballero O, Quintero J. Concordance between the determination of antinuclear antibodies by immunofluorescence and linear immunoassay. Med Lab. 2011;17(9):429-43.
22. Arevalo J. Prevalence of expression of ANA antinuclear antibodies in samples submitted from patients with clinical suspicion of autoimmune disease, by means of a relationship with fluorescent patterns in a clinical referral laboratory. Quito, 2017. In: Clinical biochemistry title thesis. Quito, Ecuador: Central University of Ecuador; 2018, 97 pp.
23. De Beeck K, Vermeersch P, Verschueren P. Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay. Autoimmun Rev. 2011;10(12):801-8.
24. Ray S, Sonthalia N, Autoimmune Disorders Kundu S. An Overview of Molecular and Cellular Basis in Todays Perspective. J Clin Cell Immunol. 2012;10(3):1-12.
25. Cascón P, Ortiz J, Pereira A. Interpretation of immunological tests in primary care. Jano. 2009;1754(1):29-33.
26. Fairweather D, Frisancho S, Rose N. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol. 2008;173(3):600-9.
27. Adams B, Mutasim D. Diagnostic importance of the determination of antinuclear antibodies. Int J Res Dermatol. 2001;4(3):887-91.
28. Castro C, Gourley M. Diagnostic testing and interpretation of tests for autoimmunity. J Allergy Clin Immunol.
2010;125(2): S238-47.
29. Antinuclear Antibodies Tan E. Diagnostic Markers for Autoimmune Diseases and Probes for Cell Biology. Adv Immunol. 1989;44(1):93-151.
30. Marhuenda A, Ramos M. Clinical significance of antinuclear antibodies. JANO. 2005;1578(1):85-90.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.